Lilly(LLY) CNBC·2025-02-20 13:50Core Insights - Eli Lilly aims to leverage its financial success from GLP-1 drugs to invest in challenging health issues such as heart disease, hearing loss, addiction, chronic pain, Alzheimer's, and ALS [1][2] - The company has experienced significant growth, with sales increasing nearly 60% since the approval of its diabetes and obesity drug Mounjaro in 2022, and its stock price rising 268% over the past three years, resulting in a market cap of $823 billion [2] Alzheimer's Research - Lilly is currently testing its drug Kisunla, a monoclonal antibody, for its potential to prevent Alzheimer's disease by removing amyloid plaques from the brain [3] - The company is actively recruiting seniors for trials in various community locations to assess their risk of Alzheimer's, with participants receiving either Kisunla or a placebo [4] - The potential success of Kisunla could revolutionize the approach to diagnosing and treating Alzheimer's, marking a significant inflection point in the use of such medicines [5]